Comparison of effects of sitagliptin and metformin on motor function and cognitive function in patients with Parkinson's disease complicated with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029465

Enrollment

Unknown

Registered

2020-02-02

Start date

2020-04-06

Completion date

Unknown

Last updated

2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Sitagliptin group:Sitagliptin 100mg/d for 52 weeks

metformin group:metformin 1000-1500mg/d for 52 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged from 18 to 75 years old; 2. The score of Hoehn and Yahr =18.5kg/m2.

Exclusion criteria

Exclusion criteria: 1. Using DPP4 inhibitor or GLP1 analogues within 3 months before trial initiation; 2. eGFR3 ULN or TBIL>2 ULN).

Design outcomes

Primary

Measure	Time frame
The sore of MDS-UPDRS part III;The sore of Mattis DRS-2;	—

Secondary

Measure	Time frame
Levodopa equivalent dose;Glycosylated Haemoglobin (HbA1c);Lipid profile;Folic acid;Vitamin B12;Homocysteine;	—

Countries

China

Contacts

Public ContactFan Ping

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

pingfan6779@163.com+86 13651091819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026